Drug Recall for DBL™ Vancomycin 500mg Vials

HPS Pharmacies wish to advise that Pfizer Australia, in consultation with the Therapeutic Goods Administration (TGA), has initiated a drug recall for DBL™ Vancomycin 500mg vials as follows:

DBL™ Vancomycin Vials
Vancomycin 500mg
ARTG 62603

This recall has been initiated after an internal investigation found batches to have out of specification stability results. These results do not meet the shelf-life specification for potency or have atypically declining potency over the 30-month product shelf-life.

The following batches are affected:

• J036913AA (expiry 06-2023)
• J036913BA (expiry 06-2023)

Please inspect your stock and quarantine all affected products. If HPS Pharmacies provide imprest management services to your facility, an HPS representative will inspect all stock stored in the designated imprest areas at the earliest opportunity. All affected products will be quarantined for return to the supplier and HPS Pharmacies will arrange for replacement stock as soon as possible. An HPS Pharmacies staff member will contact senior medical and nursing staff if there is an immediate impact to your facility.

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.

Download PDF